Aim: The cytotoxic effects of graphene oxide nanoparticles (GONPs) using MTT assays, observance of apoptotic markers, and oxidative stress were outlined. Materials & methods: Rat embryonic fibrobla...
6 July 2019 in International Journal of Research in Pharmaceutical Sciences
Taurine is sulfur containing semi-essential amino acid that has important roles in many biological processes, but its effect on glucose homeostasis, weight, growth and bone mineralization weren’t well defined. Objectives: the evaluation of oral Taurine effects has used for 3 months on bone mineralization biomarker, glycemic control and body weight in type ll diabetic patients. Methods: the interventional double-blind placebo-controlled study in which 80 patients with type 2 diabetes mellitus (age range 45-55) assigned in either control (n=40), or study group the (n=40) group. The last group has received a 1000mg capsule of Taurine once a day for three months. Parameters measured were serum calcium, 25(OH) vitamin D and osteocalcin, NTX-1 HbA1C% with fasting blood glucose before and after 3 months. Results: taurine led to significant (p<0.05) rise in osteocalcin, significant lowering in body weight, BMI and there were no significant changes in serum calcium, NTX-1, Vitamin D, HbA1C and fasting blood glucose, all as compared with the control value. Conclusions: the 3 months of oral Taurine are used in type II diabetic patients may modulate bone mineralization represented by elevation of osteocalcin and reduction of body weight, but has no significant effect on glycemic control and did not reduce HbA1C%.
The search for new molecules targeting SARS-CoV-2 has been a priority since 2020. The continuous evolution of new mutants increases the need for more research in the area. One way to find new leads is to repurpose existing drugs and molecules against the required target. Here, we present the in vitro and in silico screening of ten previously synthesized and reported compounds as anti-COVID 19 agents. The compounds were screened in vitro against VERO-E6 cells to find their Cytotoxic Concentration (CC50) and their Inhibitory Concentration (IC50). Compounds 1, 2, and 5 revealed a promising anti-SARS-CoV-2 of (IC50 = 2.4, 11.2 and 2.8 µM), respectively while compounds 3 and 7 showed moderate activity of (IC50 = 17.8 and 26.1 µM) compared to Chloroquine which showed an IC50 of 24.9 µM. Among tested compounds, 1 showed the highest selectivity (CC50/IC50) of 192.8. Docking, molecular dynamics and ADME studies were done to investigate potential interactions between compounds and SARS-CoV-2 targets as well as to study the possibility of using them as lead compounds.
Since the COVID-19 pandemic alarm was made by the severe acute respiratory syndrome (SARS)-coronavirus (CoV) 2, several institutions and agencies have pursued to clarify the viral virulence and infectivity. The fast propagation of this virus leads to an unprecedented rise in the number of cases worldwide. COVID-19 virus is exceptionally contagious that spreads through droplets, respiratory secretions, and direct contact. The enveloped, single-stranded RNA virus has a specific envelop region called (S) region encoding (S protein) that specifically binds to the host cell receptor. Viral infection requires receptors' participation on the host cell membrane's surface, a key- step for the viral invasion of susceptible cells. Recently, the Italian alpha 1 antitrypsin Registry results showed a close geographic distribution of positive cases like the one recorded for SARS -CoV-2 infection. AAT deficient patients presented with the highest infection rates. They were giving attention to alpha 1 antitrypsin AAT's role in COVID-19 infection. Alpha 1 antitrypsin deficiency (AATD) is undoubtedly the most common genetic condition in adults. AATD is characterized by decreased serum levels or impaired AAT action, raising the risk of developing many diseases, particularly pulmonary emphysema cirrhosis of the liver. This review will discuss the main immunological properties that AAT has as a protective agent against the infection and possible therapeutic application.
Cyclin-dependent kinases (CDKs) are ser/thr kinases that affect cell cycle progression by phosphorylation of target substrates in a regulated manner. The catalytic mechanisms of these enzymes work in complex with regulatory cyclin subunits. Their activities are tightly controlled by CKIs and phosphorylation events. The mechanisms of malignant transformation that affect CDK include cyclin overexpression, CKI loss, alteration of upstream signaling pathways, and failure to trigger the compensatory mechanisms necessary to inhibit CDK activity. Ultimately, this results in the disruption of the cell cycle which leads to dysregulation of cellular proliferation and genomic instability. This comprehensive review focuses on the current status of CDK-targeted cancer therapeutics, and the types of principles and mechanisms employed in structure-based drug design. We review how CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) in hormone receptor-positive breast cancer have changed treatment paradigms and the proof of concept for selective CDK targeting as a therapeutic strategy. The acquisition of resistance, however, is not without challenges - alterations to the Rb pathway, upregulation of cyclin E1, and activation of alternative signalling network PI3K/mTOR and RTK/RAS pathways. We present a critical review of recent strategies to overcome resistance including rational drug combination therapy, new generation inhibitors of alternative isoforms of CDKs (CDK2, CDK7, CDK9, and CDK12), and novel approaches applying PROTACs and molecular glue therapies to lead to degradation of CDK proteins. In addition, biomarker-based patient stratification is examined for harnessing precision medicine in drug delivery outcomes. The development of CDK inhibitors currently faces challenges in achieving selectivity with potency, off-target toxicities, and predictive biomarkers of response. Future research will examine synthetic lethal interactions, immunological activities following CDK inhibition, and combination with other treatment options including new forms of immunotherapy and epigenetic modulators. This review summarises what we know so far and points out the most promising targets for developing more effective and personalised CDK targeted therapies.